301246 Stock Overview
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.66 |
| 52 Week High | CN¥37.74 |
| 52 Week Low | CN¥14.16 |
| Beta | 0 |
| 1 Month Change | -8.74% |
| 3 Month Change | -31.62% |
| 1 Year Change | -52.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.67% |
Recent News & Updates
Shareholder Returns
| 301246 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.7% | 4.9% | 2.1% |
| 1Y | -52.7% | -13.4% | -14.2% |
Return vs Industry: 301246 underperformed the CN Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 301246 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
| 301246 volatility | |
|---|---|
| 301246 Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 301246's share price has been volatile over the past 3 months.
Volatility Over Time: 301246's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,164 | Shuangxi Xu | www.hbhypharm.com |
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally. It provides active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, triamine, diacetyl guanine, guanine, and diacetylacyclovir; organic chemical raw materials comprising fluoride salts, glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. The company was founded in 2002 and is headquartered in Huanggang, China.
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Fundamentals Summary
| 301246 fundamental statistics | |
|---|---|
| Market cap | CN¥6.26b |
| Earnings (TTM) | CN¥53.62m |
| Revenue (TTM) | CN¥1.98b |
116.8x
P/E Ratio3.2x
P/S RatioIs 301246 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301246 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.98b |
| Cost of Revenue | CN¥1.74b |
| Gross Profit | CN¥236.76m |
| Other Expenses | CN¥183.14m |
| Earnings | CN¥53.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 11.98% |
| Net Profit Margin | 2.71% |
| Debt/Equity Ratio | 7.7% |
How did 301246 perform over the long term?
See historical performance and comparison